EUVIMEDEUVIMED entdecken
Crossref

Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort

William Mantilla iD, Maríafernanda Gonzalez iD, Sebastián Rojas iD, Mariana Borras-Osorio iD, Nicolas Molano-Gonzalez, Diego Moran iD, Joaquín Hernando Guerra iD, Oscar Romero iD, Isabel Munevar iD, ICAROS Research Group

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von William Mantilla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center CTIC, Bogota, Colombia. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Breast cancer (BC) is the most frequent neoplasm in women in Colombia and is associated with a higher mortality rate than in other countries and regions. Neoadjuvant chemotherapy (NACT) has become a standard treatment in locally advanced BC and provides an opportunity to improve clinical outcomes in BC. This study aims to describe characteristics, treatment patterns, and outcomes after NACT in a cohort of Colombian patients with BC. METHODS We performed a retrospective cohort study. We included adult patients with BC treated with NACT. Clinical charts were retrospectively reviewed. Descriptive statistics and time to event for overall survival analyses were performed. Recursive partitioning was performed for survival curves to assess the complex relationship between survival times and other variables. RESULTS Three hundred and fourteen patients were included for analysis. The pathologic complete response after neoadjuvant chemotherapy (ypCR) rate was 34.4%, with a higher ypCR in triple-negative BC (TNBC; 46.9%) and human epidermal growth factor receptor 2–positive BC (72.7%). Those who did not achieve ypCR had a higher percentage of death and relapse. The median follow-up was 4.9 years, with an 88.2% 5-year overall survival (OS). CONCLUSION A total of 62.6% of the total patients identified were not treated with NACT, indicating a low utilization. Our global ypCR rate was higher when compared with similar studies in Colombia, likely because of differences in the NACT treatment regimens. ypCR was only associated with OS in the TNBC subgroup, emphasizing the importance of pursuing ypCR in these patients. We consider the use of NACT a valuable opportunity to implement innovative treatment approaches that improve outcomes in Colombian patients with BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedColombiaAdultAgedChemotherapy, AdjuvantTreatment Outcome

Autor:innen und Institutionen

  • Breast Cancer Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center CTIC, Bogota, Colombia.
  • Fundación Cardioinfantil-Instituto de Cardiologia, Bogota, Colombia.
  • Internal Medicine Department, Clínica Sanitas 103, Bogota, Colombia.
  • Internal Medicine Department, Hospital Universitario Mayor Mederi, Bogota, Colombia.
  • ICAROS Research Group, Bogota, Colombia.
  • Clinical Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.

ORCID-Profile: William Mantilla, Maríafernanda Gonzalez, Sebastián Rojas, Mariana Borras-Osorio, Diego Moran, Joaquín Hernando Guerra, Oscar Romero, Isabel Munevar

Zitieren

APA

Mantilla, W., Gonzalez, M., Rojas, S., Borras-Osorio, M., Molano-Gonzalez, N., Moran, D., Guerra, J. H., Romero, O., Munevar, I., & ICAROS Research Group (2024). Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort. JCO Global Oncology. https://doi.org/10.1200/go.23.00187

Vancouver

Mantilla W, Gonzalez M, Rojas S, Borras-Osorio M, Molano-Gonzalez N, Moran D, et al. Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort. JCO Global Oncology. 2024. doi:10.1200/go.23.00187

BibTeX
@article{Mantilla2024,
  author = {Mantilla, William and Gonzalez, Maríafernanda and Rojas, Sebastián and Borras-Osorio, Mariana and Molano-Gonzalez, Nicolas and Moran, Diego and Guerra, Joaquín Hernando and Romero, Oscar and Munevar, Isabel and ICAROS Research Group, ICAROS Research Group},
  title = {Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00187}
}
Kostenlos starten →